Dopamine Agonist Market Size is valued at USD 1.4 billion in 2024 and is predicted to reach USD 2.9 billion by the year 2034 at a 7.4% CAGR during the forecast period for 2025-2034.
Dopamine agonists are a class of drugs that imitate the effects of dopamine by activating dopamine receptors in the brain. They are mostly used to treat illnesses where dopamine plays a part in the disease process, such as Parkinson's disease, where dopamine levels are low. The growing incidence of Parkinson's disease, restless legs syndrome, and other neurological conditions that call for dopamine-modulating therapies is the main driver of the market. The occurrence of these disorders is predicted to rise as the world's population ages, which will increase demand even further. Furthermore, improvements in medication formulations, like transdermal and extended-release alternatives, improve patient compliance and increase market potential. The creation of new dopamine agonists with enhanced safety and efficacy profiles is also anticipated to propel market expansion.
However, the primary barriers to market expansion are the high expense of dopamine agonist therapy and the possibility of adverse effects like hallucinations and problems with impulse control. Moreover, the development of targeted medicines for Parkinson's disease and other dopamine-related illnesses, as well as the increased emphasis on precision medicine, provide market participants with substantial prospects. The development of healthcare infrastructure in developing nations is also anticipated to propel market expansion.
Competitive Landscape
Some Major Key Players In The Dopamine Agonist Market:
• Teva Pharmaceutical Industries Ltd
• GSK plc.
• Supernus Pharmaceuticals, Inc.
• Lundbeck A/S
• Amneal Pharmaceuticals LLC
• UCB Pharma
• Novartis AG
• VeroScience LLC.
• Pfizer Inc.
• Boehringer Ingelheim Pharmaceuticals, Inc.
• Other Market Players
Market Segmentation:
The Dopamine Agonist market is segmented based on drug, application, route of administration, and distribution channel. As per the drug, the market is segmented into Ergot Alkaloids and Non-Ergot Dopamine Agonists. By application, the market is segmented into Parkinson's Disease, Restless Legs Syndrome (RLS), Hyperprolactinemia, and Others. By route of administration (ROA), the market is segmented into Oral, Injectable, and Others. The distribution channel category is further classified into Hospital Pharmacies, Retail Pharmacies, and Other Pharmacies.
Based On The Drug, The Non-Ergot Dopamine Agonists Segment Is Accounted As A Major Contributor To The Dopamine Agonist Market
The Non-Ergot Dopamine Agonists category is expected to hold a major global market share in 2021. Their enhanced safety profile explains this dominance, less likelihood of side effects associated with fibrosis, and great effectiveness in treating neurological conditions such as Parkinson's disease and restless legs syndrome (RLS). In contrast to its ergot-derived equivalents, non-ergot dopamine agonists, including pramipexole, ropinirole, rotigotine, and apomorphine have become widely used because of their better tolerability and lower risk of cardiovascular problems.
Parkinson's Disease Segment To Witness Growth At A Rapid Rate
The use of dopamine agonists is being greatly influenced by the increasing prevalence of Parkinson's disease (PD), which is predicted to reach 1.2 million cases by 2030 in the United States, with 90,000 new diagnoses every year. Over 10 million individuals worldwide have Parkinson's disease (PD), the second most common neurological disease, with men 1.5 times more likely to develop it than women. The need for affordable treatments is highlighted by the economic burden, which is estimated to be USD 52 billion yearly in the United States and includes treatment, missed wages, and social security expenses. Given that the average annual cost of medications is USD 2,500, there is a growing need for long-acting, reasonably priced dopamine agonists, including generic versions, which is driving market growth.
In The Region, The North American Dopamine Agonist Market Holds A Significant Revenue Share
The North American Dopamine Agonist market is expected to register the highest market share in revenue in the near future. Increases in hyperprolactinemia, Parkinson's disease, and restless legs syndrome (RLS) are driving market growth. Injectable and oral medications are examples of new drug formulations that are improving patient accessibility and compliance. The usage of ergot alkaloids and non-ergot dopamine agonists, as well as expanding biopharmaceutical research and regulatory approvals, are further factors propelling market expansion. Targeted medications are becoming more and more necessary, and hospital and retail pharmacies remain crucial distribution channels. In addition, Asia Pacific is projected to grow rapidly in the global Dopamine Agonist market because the burden of chronic diseases is growing, access to healthcare is improving, and investments in the biotech sector are growing. Increasing clinical studies, domestic medication production, and regulatory clearances are helping countries like China, India, and Japan lead this trend. Technological developments in injectable and oral medication delivery are also propelling industry expansion.
Recent Developments:
• August 2024: AbbVie Inc. acquired Cerevel Therapeutics, a clinical-stage biopharmaceutical business that specializes in neurological disorders, for USD 8.7 billion. By strengthening AbbVie's position in the neuroscience market, this acquisition may spur dopamine agonist therapy innovation and increase competition in neurological disease treatments.
Dopamine Agonist Market Report Scope:
|
Report Attribute |
Specifications |
|
Market Size Value In 2024 |
USD 1.4 Billion |
|
Revenue Forecast In 2034 |
USD 2.9 Billion |
|
Growth Rate CAGR |
CAGR of 7.4% from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Mn and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
Drug, Application, Route Of Administration, And Distribution Channel |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Teva Pharmaceutical Industries Ltd, GSK plc., Supernus Pharmaceuticals, Inc., H. Lundbeck A/S, Amneal Pharmaceuticals LLC, UCB Pharma, Novartis AG, VeroScience LLC., Pfizer Inc., and Boehringer Ingelheim Pharmaceuticals, Inc. |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
